RxDoctor Payments Data

Ahmed Numaan, MD

Psychiatry · Sheboygan, WINPI 1437168358

Payments from drug & device makers

$1,419in general payments, 2019–2025

Across 33 payments — averaging $43.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$524
  • AbbVie$287
  • Axsome Therapeutics, Inc.$184
  • Teva Pharmaceuticals USA, Inc.$162
  • Otsuka America Pharmaceutical, Inc.$97
  • Vanda Pharmaceuticals Inc.$49
  • plus $116 from 4 others

What the payments were for

  • Food & beverage$1,419100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,419 in reported general payments places this provider in the 80th percentile of 543 psychiatry providers in Wisconsin.

See all psychiatry providers in Wisconsin

Medicare billing

Part B allowed, 2024
$154,430
Medicare patients
364
Services billed
1,515

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl42$47,746
RexultiBrexpiprazole16$24,426
VraylarCariprazine Hcl17$20,745
Mirtazapine171$4,904
Desvenlafaxine Succinate ErDesvenlafaxine Succinate87$4,690
Aripiprazole56$4,534
Lisdexamfetamine Dimesylate20$3,957
Duloxetine Hcl68$2,645
Bupropion XlBupropion Hcl124$2,498
Quetiapine Fumarate105$1,865
Trazodone Hcl162$1,813
Atomoxetine Hcl12$1,641
Venlafaxine Hcl ErVenlafaxine Hcl87$1,367
Escitalopram Oxalate136$1,331
Divalproex Sodium ErDivalproex Sodium25$1,168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$97$24,42616 claims
AbbVieVraylar$287$20,74517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 543 psychiatry providers in Wisconsin.

Other psychiatry in Sheboygan

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →